sponsored
PatientsVille.com Logo

PatientsVille

Zithromax Medical Research Studies

Up-to-date List of Zithromax Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Zithromax Medical Research Studies

Rank Status Study
1 Not yet recruiting Mortality Reduction After Oral Azithromycin: Mortality Study
Condition: Childhood Mortality
Interventions: Drug: Azithromycin;   Drug: Placebo
Outcome Measures: All-cause Mortality Rate in children aged 1-60 months;   Cause-specific Mortality Rate in children aged 1-60 months, as assessed from verbal autopsy;   Cost-effectiveness of mass azithromycin administration, per averted childhood death;   All-cause and cause-specific health clinic visits in 1-60 month-old children
2 Not yet recruiting Mortality Reduction After Oral Azithromycin: Morbidity Study
Condition: Childhood Mortality
Interventions: Drug: Azithromycin;   Drug: Placebo
Outcome Measures: Presence of malaria parasites on thick blood smear in children 1-60 months;   Fraction of isolates of pneumococcus exhibiting macrolide resistance by nasopharyngeal swabs in children 1-60 months;   Fraction of isolates of Staphylococcus aureus exhibiting macrolide resistance by nasal swabs in children 1-60 months;   Fraction of isolates of Streptococcus pyogenes exhibiting macrolide resistance by oropharyngeal swabs in children 1-60 months;   Evidence of E. coli macrolide resistance in stool specimens in children 1-60 months;   Fraction of conjunctival swabs yielding ocular chlamydia in children 1-60 months;   Height over time in children aged 1-60 months;   Presence of malaria gametocytes, and density of malaria parasites and gametocytes, in children 1-60 months;   Rates of malaria parasitemia among children 1-59.9 months.;   Hemoglobin concentration and presence of anemia (hemoglobin <11 g/dL) in children 1-60 months;   Nasopharyngeal pneumococcal macrolide resistance in individuals 7-12 years;   Nasopharyngeal pneumococcal macrolide resistance in children aged 1-60 months seen in local health clinics for a respiratory complaint;   Rates of acute respiratory illness among children 1-59.9 months.;   Carriage rates and proportions of S. pneumoniae isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months.;   Carriage rates and proportions of S. pneumoniae isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months hospitalized for pneumonia and diarrhea.;   Presence of the trachoma grades "follicular trachoma" (TF) and "intense inflammatory trachoma" (TI), as defined by the WHO simplified grading system, in children 1-60 months;   Trachoma infection and antibody status in children (1-60 months);   Rates of diarrhea among children 1-59.9 months.;   Carriage rates and proportions E. coli isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months;   Carriage rates and proportions of E. coli isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months hospitalized for pneumonia and diarrhea.;   Studies of intestinal permeability and inflammation, microbial translocation, and immune activation assessed through venous sampling of children 6 months;   Studies of intestinal permeability and inflammation, microbial translocation, and immune activation assessed through urine samples for L:M ratios of children 6 months;   Studies of intestinal permeability and inflammation, microbial translocation, and immune activation assessed through stool (fecal neopterin) of children 6 months;   Nasopharyngeal methicillin-resistant Staphylococcus aureus in children 1-60 months;   Carriage rates and proportions of S. aureus isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months.;   Carriage rates and proportions of S. aureus isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months hospitalized for pneumonia and diarrhea.;   Nasopharyngeal pneumococcal resistance to penicillin and clindamycin in children 1-60 months;   Nasopharyngeal pneumococcal macrolide resistance determinants (ermB and mefA), serotype, and multilocus sequence type in children 1-60 months;   Oropharyngeal Streptococcus pyogenes macrolide resistance to penicillin and clindamycin in children 1-60 months;   Oropharyngeal Streptococcus pyogenes macrolide resistance determinants (mefA, ermB, ermTR) in children 1-60 months;   Microbial diversity in the conjunctival, nasopharyngeal, nasal, oropharyngeal, and intestinal microbiomes of children aged 1-60 months;   Serology for exposure to exotic pathogens cross sectional sample of children aged 1-60 months;   Knee-heel length and head circumference over time in children aged 1-60 months;   Commensal and diarrheagenic E. coli carriage in stool of children aged 1-60 months
3 Recruiting Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants
Condition: Ureaplasma Infections
Interventions: Drug: Azithromycin;   Drug: Placebo (for azithromycin)
Outcome Measures: Survival with microbiological eradication of Ureaplasma;   Physiologic defined bronchopulmonary dysplasia (BPD) at 36 weeks post menstrual age;   Death or Neurodevelopmental impairment;   Pulmonary impairment;   Death;   Duration of positive pressure support;   Duration of oxygen supplementation;   Air leaks;   Received postnatal steroids;   Received Non-Study antibiotics;   Pharmacokinetics (PK)/Pharmacodynamics (PD) modelling of time course of azithromycin plasma concentrations
4 Not yet recruiting Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis
Conditions: Malaria, Falciparum;   Chloroquine;   Azithromycin;   Immunization
Interventions: Drug: Azithromycin capsules;   Drug: Placebo;   Biological: Immunization with falciparum;   Drug: Atovaquone/Proguanil;   Biological: Challenge with falciparum
Outcome Measures: Volunteers falciparum positive by thick smear;   Duration of pre-patent period by thick smear;   Kinetics of parasitemia by PCR;   Adverse events;   Immune responses
5 Recruiting Trial for the Treatment of Acute Asthma in Wheezy Pre-school Aged Children
Condition: Asthma
Interventions: Drug: Azithromycin;   Drug: Suspension Placebo
Outcome Measures: To determine if treatment of pre-school children with a history of wheeze who present to an Emergency department (ED) with an acute wheezing episode with Azithromycin for 5 days will resolve their symptoms more quickly;   Treatment of pre-school children with acute wheezing symptoms with 5 days of azithromycin will cause these children to use less rescue beta2 agonists than those treated with placebo;   Treatment of pre-school children with acute wheezing symptoms with 5 days of azithromycin will allow these children to remain free of subsequent wheezy episodes longer than those treated with placebo.
6 Not yet recruiting Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection
Conditions: Ocular Inflammation;   Infection Associated Blepharitis;   Keratitis;   Conjunctivitis, Bacterial
Interventions: Drug: azithromycin 1.5%/Loteprednol 0,5% + placebo;   Drug: azithromycin 1.5% + Loteprednol 0,5% (separately)
Outcome Measures: Clinical cure;   irradication of pathogens
7 Not yet recruiting Belgian Trial With Azithromycin During Acute COPD Exacerbations
Condition: Chronic Obstructive Pulmonary Disease
Intervention: Drug: Azithromycin
Outcome Measures: Time to treatment failure;   Number of treatment failures;   Time to new exacerbation;   Number of new exacerbations;   Rate of exacerbations;   Days of hospitalisation;   Days of intensive care;   Symptom and quality of life scores;   Pre- and post-bronchodilator FEV1;   Total dose of systemic steroids;   Total days of antibiotic use;   Number of home physician contacts;   Average cost of hospitalization
8 Recruiting Peri-operative Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation
Condition: Disorder Related to Lung Transplantation
Interventions: Drug: Azithromycin;   Drug: Ora-Plus
Outcome Measures: Mean forced expiratory volume at one second (FEV1, %pred);   Length of intubation;   Length of Intensive Care Unit (ICU) stay;   Length of hospital stay;   Partial Pressure of Oxygen in Arterial Blood over fraction of inspired oxygen fraction - ratio (PaO2/FiO2);   Primary graft dysfunction (PGD) prevalence and score;   6-minute walking distance;   Acute rejection (grade A; grade B) prevalence/severity;   Broncho-alveolar lavage neutrophilia and cytokine/protein profile;   Airway colonization;   Plasma C-reactive protein levels;   Mortality;   Ventilator-free days
9 Recruiting AZithromycin Against pLacebo in Exacerbations of Asthma
Condition: Asthma
Interventions: Drug: Zithromax;   Drug: Placebo
Outcome Measures: Diary card summary symptom score;   Quality of life;   Time to 50% reduction in symptom score;   Pulmonary Function tests
10 Recruiting A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial
Condition: Trachoma
Intervention: Other: Surveillance and treatment with azithromycin of newcomer and traveler families
Outcome Measures: The proportion of communities with C. trachomatis infection prevalence of 1% or below;   The proportion of communities with clinical trachoma prevalence of 5% or below;   The trajectory of change in prevalence of infection with C. trachomatis and clinical trachoma;   The community prevalence of new infections of C. trachomatis and clinical trachoma identified;   The presence of active trachoma in children;   The presence of trachomatous scarring in women
11 Recruiting PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric Patients
Conditions: Pharyngitis;   Tonsillitis
Intervention: Drug: Azithromycin
Outcome Measure: Best corrected visual acuity (distance), color vision, Amsler grid testing, anterior segment biomicroscopy, and fundus examination
12 Recruiting Azithromycin for Children Hospitalized With Asthma
Condition: Asthma
Interventions: Drug: Azithromycin;   Drug: Placebo
Outcome Measures: Length of Stay;   Readmission rate;   School missed;   Work missed;   Emergency room visits;   Physician office visits;   Recurrence of asthma symptoms;   Steriod courses
13 Recruiting Trial Of Azithromycin In Campylobacter Concisus Patients With Diarrhea
Conditions: Diarrhea;   Fever;   Vomiting;   Abdominal Pain
Interventions: Drug: azithromycin;   Drug: Placebo
Outcome Measures: Duration of diarrhea in days;   number of stools/day
14 Unknown  Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis
Condition: Cutaneous Leishmaniasis
Interventions: Drug: N-metil glucamine;   Drug: Azithromycin
Outcome Measures: Proportion of clinically cured patients;   Proportion of patients with failure;   Occurrence of mucosal lesions after treatment;   Proportion of patients presenting new lesions;   Proportion of adverse events on each treatment group
15 Recruiting Drug Interaction Study of Azithromycin and Theophylline
Conditions: Chronic Obstructive Pulmonary Disease;   Asthma
Interventions: Drug: Theophylline with azithromycin;   Drug: Theophylline alone
Outcome Measure: steady-state plasma concentration of theophylline
16 Recruiting Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: Azithromycin + Metronidazole;   Drug: Metronidazole
Outcome Measures: Response rate at 8 weeks defined as a drop in PCDAI (Pediatric Crohn's Disease Activity Index ) of at least 12.5 points (or remission without steroids, intention to treat principle);   Normalization of CRP ( CRP ≤0.5 mg/dL).;   Fecal calprotectin at 8 weeks .
17 Unknown  The Efficacy of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease
Conditions: Cat-scratch Disease;   Bartonella Infections
Interventions: Drug: prednison and azithromycin;   Drug: prednison, azithromycin;   Drug: prednison, Azenil
Outcome Measure: Severity score of lymphadenitis using a lymphadenitis Score (LS).
18 Recruiting Efficacy of Azithromycin Prophylaxis in Preventing Recurrent Acute Sinusitis in Children
Condition: Sinusitis
Interventions: Drug: placebo;   Drug: azithromycin
Outcome Measure: frequence of acute sinusitis during 12 mouths of study period
19 Recruiting Prevention of Bacterial Infections in Newborn
Condition: Neonatal Infection
Intervention: Drug: Azithromycin and Placebo
Outcome Measures: the prevalence of nasopharyngeal carriage of the newborn of any of the following bacteria: 1) Group B Streptococci (GBS) , 2) S.pneumoniae and 3) S.aureus;   Vaginal bacterial Group B Streptococci(GBS), S.pneumoniae and S.aureus) carriage at day six post-delivery. Vaginal bacterial (GBS, S.pneumoniae and S.aureus) carriage at day 8-10 post-delivery
20 Recruiting Antibiotic Treatment Trial for the PANDAS/PANS Phenotype
Conditions: Pediatric Acute Onset Neuropsychiatric Syndrome (PANS);   Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections;   Obsessive Compulsive Disorder (OCD)
Interventions: Drug: Azithromycin;   Drug: Placebo
Outcome Measures: Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS);   Clinical Global Impressions;   Screen for Child Anxiety Related Disorders

These studies may lead to new treatments and are adding insight into Zithromax etiology and treatment.

A major focus of Zithromax research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Zithromax